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speciﬁed subtype. Nearly half received immunoglobulins, one in sixwas
on immunosuppressants and over a quarter, were untreated, although
their disease activity status was not speciﬁed. Mean disease duration
was 7 years with however, a very wide range of 9 weeks up to
42 years. MSRV-Env expressions were found signiﬁcantly higher in
CIDP patients than in healthy blood donors and, of note, inversely corre-Chronic inﬂammatory demyelinating polyneuropathy (CIDP) is a higher in CIDP than in all controls, this being for the former, a contradic-relatively rare, treatable, peripheral nerve disorder of autoimmune
basis. Its prevalence is probably only around 5 per 100,000, with an in-
cidence of b1 per 100,000 per year (Rajabally et al., 2009). CIDP causes
in its typical form, symmetrical proximal and distal weakness of the 4
limbs. There are several atypical forms. These are, importantly, not
much more uncommon than typical CIDP and have varied presenta-
tions, including, pure motor, pure sensory, focal or multifocal subtypes
(Van den Bergh et al., 2010). Onset is usually progressive N8 weeks al-
though acute-onset forms are well documented. Available evidence-
based treatments for CIDP include corticosteroids, immunoglobulins
and plasma exchanges. There remains a proportion of patients who
remain refractory to these therapies, individually or in combination.
Although several immunosuppressant drugs have been tried, there is
currently no evidence of efﬁcacy for any of them. Newer therapies
require consideration, particularly for refractory patients but also to
provide more options generally for this patient population.
In this issue of EBioMedicine, Faucard et al. (2016) describe their
work on 51 patients with CIDP from 2 centres, investigated for the
pro-inﬂammatory protein MSRV-Env (Multiple Sclerosis Associated
Retroviral element), encoded by the Human Endogenous Retrovirus
HERV-W. MSRV-Env had been previously detected in a small number
of patients with CIDP used as neurological controls in a study of patients
with multiple sclerosis (MS). A heterogeneous group of patients with
other neurological diseases as well as healthy blood donors was used
as controls. Detailed clinical description was not available although
the majority (24 subjects) had symmetrical sensory and motor deﬁcits,m.2016.03.001.
ntre, Aston University, Aston
. This is an open access article underlating with disease duration. The expression was not high in neurologi-
cal controls. IL6 and CXCL10 chemokine levels were both signiﬁcantly
tory ﬁnding in comparison to previous studies. MSRV-Env expression
was raised in 5/7 sural nerve biopsies from CIDP patients but in neither
of 2 control biopsies. In a further experiment, the authors found that the
pro-inﬂammatory effects of MSRV-Env on human Schwann cells as
measured by IL6 and CXCL10 concentrations, were inhibited by the hu-
manized IgG4 subclass monoclonal antibody, GNbAC1. They concluded
that the autoimmune reaction in CIDP may result from TLR4-driven ac-
tivation of innate immunity by MSRV-Env protein, making it a possible
therapeutic target and raising the possibility that GNbAC1 may repre-
sent a potential innovative treatment for CIDP. This is already the
focus of phase II trials in MS (Derfuss et al., 2015).
These ﬁndings are interesting with conceivable implications for fu-
ture CIDP research. One of the main issues with the study, partly ac-
knowledged, is that of small numbers. Furthermore, the breakdown
per CIDP subtype is imprecise, and leaves still lesser numbers which
prevents any meaningful analysis per subgroup. This is however of
paramount importance as different CIDP subtypes may have varying
underlying pathophysiology, the disorder representing a spectrum of
related conditions rather than an entity per se (Mathey et al., 2015). Al-
though thought to be both implicated, relative contributions of T-cell
and antibody-mediated mechanisms are uncertain. It has been sug-
gested that Lewis–Sumner syndrome for instance may involve cellular
immunity as opposed to typical CIDP which may instead relate to
antibody-mediated mechanisms (Kuwabara et al., 2015). As a result, it
is possible that Lewis–Sumner syndrome may be less responsive to
main CIDP therapies (Kuwabara et al., 2015). In recent years, studies
on antibody speciﬁcity in CIDP have focused on the node of Ranvier
(Mathey et al., 2015). A minority of CIDP patients, some with speciﬁc
phenotypes and lack of response to usual therapies, have been identi-
ﬁed as demonstrating antibodies to a number of nodal proteins. As an
illustrative example, anti-neurofascin-155 IgG4 antibody-positive
cases, with a characteristic phenotype of early-onset ataxia, tremorthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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unresponsive to steroids or immunoglobulins (Devaux et al., 2016),
although may show some response to the anti-CD20 monoclonal anti-
body, rituximab (Querol et al., 2015).
The heterogeneity of CIDP is becoming more and more evident and
studies combining CIDP patients for search of biomarkers and potential
therapeutic targets, are in these circumstances of uncertain value,
particularly if numbers analysed are small. The tentation to use entire
cohorts is understandable for a disorder of such low prevalence, al-
though results obtained by combining cases of disorders, of ultimately
different pathophysiological basis, will always be difﬁcult to interpret.
The comparison with MS by Faucard et al. (2016) is interesting, al-
though considerable progress has been achieved in MS itself in terms
of phenotyping and subsequent differentiation of disease subtype path-
ophysiological differences. Studies in MS have otherwise shown that
MSRV-Env expression correlates with plaque activity (Mameli et al.,
2007), clinical progression and prognosis (Sotgiu et al., 2010). The
same does not appear proven for CIDP, the current study demonstrating
higher expression in early disease stages in a heterogeneously treated
cohort with a proportion of untreated subjects possibly in remission,
with very limited nerve histopathological samples. These samples
themselves, as opposed to MS, furthermore originate from a nerve not
necessarily affected by the disease. The results may suggest possible di-
agnostic utility as biomarker or marker of early disease activity and
could also reﬂect efﬁcacy of administered treatments, but whether
they indicate a deﬁnite potential therapeutic target in CIDP is uncertain
andwill require further study in larger, well-deﬁned and homogeneous
patient cohorts.
The differentiation of the various forms of the CIDP entity, although
previously felt of little importance for clinical practise, may become cru-
cial in the initial essential task of delineating the different disease sub-
types for such future research. Splitting rather than lumping appears
the way forward to adequately understand CIDP pathophysiology in
its likely wide diversity, although will clearly compound the difﬁculties
of studying this low-prevalence disorder and may unfortunately as a
result, also delay therapeutic progress.Disclosure
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